|Home||Company Search||Related Articles||Forum (new!)|
|Company||GlaxoSmithKline [Company Info]|
|Track this Company (an email will be sent to you everytime a report is filed about this company)|
|22nd Sep 2004||Questionable Practice||Glaxo drops appeal in Aids drug pricing case|
|A landmark legal complaint against British drug maker GlaxoSmithKline (GSK) over its Aids drug pricing and policies in South Africa will proceed after GSK dropped its public and repeated vows to appeal a decision allowing the case to go forward, according to AidsHealthcare Foundation (AHF).
Instead, GSK simply filed a required legal response to the complaint, AHF said.
The complaint was filed with South Africa's Competition Tribunal in August by AHF, the US' largest Aids organisation and several other South African Aids advocates.
AHF operates the 'Ithembalabantu' (Zulu for people's hope) clinic, a free Aids treatment clinic in Umlazi Township, KwaZulu Natal in partnership with the Network of Aids Communities of South Africa (NetCom SA) a local non-government organisation.
In the complaint, AHF and others allege that GSK has charged excessive prices for Aids drugs to the detriment of South Africans with HIV/Aids and in violation of the Competition Act.
The complaint was originally filed with the Competition Commission in January 2003.
The Treatment Action Campaign (TAC) had lodged a similar complaint with the Competition Commission against GSK during 2002.
The Competition Commission initially decided to refer that complaint, as well as the AHF complaint, to the Competition Tribunal. During December 2003, TAC and GSK concluded a settlement endorsed by the Competition Commission.
However, AHF was not a party to that settlement.
Earlier this year, the Competition Tribunal of South Africa agreed to hear the complaint, which was filed by individual South Africans and AHF.
The Tribunal also ordered GSK to pay AHF's legal costs.
|Other Reports on GlaxoSmithKline|
|29th Jan 2007||Questionable Practice||GlaxoSmithKline||GSK hid paxil suicide link|
|10th Aug 2006||Other Issue||GlaxoSmithKline||Glaxo pays $70m to end price row|
|29th Mar 2006||Questionable Practice||GlaxoSmithKline||Glaxo agrees US Paxil settlement|
|18th Mar 2005||Other Issue||GlaxoSmithKline||Glaxo shares dip on factory probe|
|6th Sep 2004||Other Issue||GlaxoSmithKline||GSK faces anti-depressant lawsuit|
|19th May 2004||Other Issue||GlaxoSmithKline||New York sues GlaxoSmithKline|
|11th May 2004||Fraud Investigation||GlaxoSmithKline||GlaxoSmithKline faces antitrust investigation|
|22nd Jan 2004||Fraud Investigation||GlaxoSmithKline||$11.1 Million settlement|
|8th Jan 2004||Questionable Practice||GlaxoSmithKline||£1.5bn Tax Bill|
|16th Dec 2003||Questionable Practice||GlaxoSmithKline||Glaxo's CEO to scoop 5.7 mln stg a year|
|25th Jun 2003||Questionable Practice||GlaxoSmithKline||FDA tells Glaxo to pull misleading Flonase ads|
|25th Jun 2003||Questionable Practice||GlaxoSmithKline||Ordered to pull misleading adverts|
|Related Reports from the Pharamaceutical Industry|
|Bristol-Myers Squibb||Questionable Practice||Bristol-Myers in $300m settlement|
|Pfizer||Questionable Practice||Pfizer to use DART for online campaigns|
|Pfizer||Questionable Practice||Pfizer claims Britons denied treatment|
|AstraZeneca||Fraud Investigation||$355m fraud fine|
|Pfizer||Questionable Practice||State Tax Report|
|© 2006 Corp-Ethics.com | Corporate Ethics|